Observational Study on SIBO in Pancreatic Cancer Patients
This study aims to understand how common Small Intestinal Bacterial Overgrowth (SIBO) is in people with pancreatic adenocarcinoma (PDAC), a type of pancreatic cancer, especially those experiencing weight loss. Researchers want to see if there's a link between SIBO and weight loss, as well as if prior pancreatic surgery plays a role. You could be eligible if you are 18 or older, have a diagnosis of pancreatic adenocarcinoma, and are experiencing weight loss. The study will involve testing for SIBO using a Lactulose Hydrogen Breath Test. The main goal is to find out the prevalence of SIBO in this group of patients. This is an observational study, meaning no specific treatments are being tested, and it plans to include 100 participants.
- Study design
- This is an observational study that plans to enroll 100 participants. It is not testing any specific interventions or drugs.
- What's involved
- You would undergo a Lactulose Hydrogen Breath Test at a screening visit. The trial record does not specify additional visits or procedures.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint, SIBO in PDAC, is measured at the screening visit. No further follow-up is specified.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Small Intestinal Bacterial Overgrowth (SIBO) in Pancreatic Adenocarcinoma (PDAC)
At a glance
Conditions
NCT06988150
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Cedars-Sinai Medical Center
Los Angeles, Californiastudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Andrew E. Hendifar, M.D., M.P.H. · PRINCIPAL_INVESTIGATOR · Cedars-Sinai Medical Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- SIBO in PDACAt Screening Visit
Assess the prevalence of SIBO in consecutive PDAC patients with clinically significant weight loss.